We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ ...

Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...

Investor sentiment toward BioNTech is cautious as the German biotech firm prepares to release its full-year results. The company’s strategic pivot from a pure-play vaccine developer to a diversified ...

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

All eyes are on the scheduled release of BioNTech's fourth-quarter and full-year 2025 financial results, set for March 10, 2026. The accompanying conference call will occur during a period of intense ...

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.